PANews reported on March 24th that, according to The Block, shares of biotechnology company NovaBay Pharmaceuticals rose 19% on March 23rd after the company announcedPANews reported on March 24th that, according to The Block, shares of biotechnology company NovaBay Pharmaceuticals rose 19% on March 23rd after the company announced

Biotechnology company NovaBay changed its name to Stablecoin Development Corporation, and its stock price surged 19%.

2026/03/24 08:37
1 min read
For feedback or concerns regarding this content, please contact us at [email protected]

PANews reported on March 24th that, according to The Block, shares of biotechnology company NovaBay Pharmaceuticals rose 19% on March 23rd after the company announced its name change to Stablecoin Development Corporation, with the stock ticker changing from NBY to SDEV. Trading is expected to begin on April 3rd. The company is strategically shifting its focus to digital assets within the Sky ecosystem. As of March 16th, it held approximately 2.06 billion SKY tokens, worth about $150 million, representing 8.8% of the total supply, and had earned approximately 26.6 million tokens as rewards through its staking program.

NovaBay's transformation began in January of this year when the company completed a $134 million private funding round supported by investors including Framework Ventures, Tether Investments, and the Sky Frontier Foundation, and began allocating capital to the SKY token. The company describes its strategy as an "on-chain holding company" model, focusing on long-term participation in protocol-layer activities.

Market Opportunity
Sky Protocol Logo
Sky Protocol Price(SKY)
$0.07205
$0.07205$0.07205
+0.41%
USD
Sky Protocol (SKY) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.